Filtered By:
Specialty: Cardiology
Management: Hospitals
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 1412 results found since Jan 2013.
PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
BMJ Open. 2022 Apr 29;12(4):e060068. doi: 10.1136/bmjopen-2021-060068.ABSTRACTINTRODUCTION: Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin-kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis.METHODS AND ANALYSIS: In this pro...
Source: Atherosclerosis - April 29, 2022 Category: Cardiology Authors: Yen-Chu Huang Chia-Hao Chang Yuan-Hsiung Tsai Hsu-Huei Weng Leng-Chieh Lin Jiann-Der Lee Source Type: research
Po-614-05 a community hospital review of watchman outcomes to determine safe discharge protocols
Left atrial appendage occlusion (LAAO) devices are increasingly used to decrease the risk of stroke in atrial fibrillation patients with contraindication to oral anticoagulation. Discharge protocols after this procedure are variable, and same day discharge (SDD) may improve inpatient bed utilization.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jill Boone Schaeffer, Diane N. Bollinger Source Type: research
Po-641-05 safety and in-hospital outcomes of left atrial appendage closure device in patients with heart failure: an analysis from the national inpatient sample database 2015-2018
Left atrial appendage occlusion (LAAO) is a procedure that has been shown to be non-inferior to oral anticoagulation for stroke prevention for patients with atrial fibrillation. There is limited data about the safety of left atrial appendage occlusion (LAAO) in patients with heart failure (HF).
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Carlos Vergara Sanchez, Michael Dangl, Michael Albosta, Ian Ergui, Karla Inestroza, Jennifer Maning, Louis Thomas Vincent, Jelani K. Grant, Bertrand Ebner, Rosario Colombo Source Type: research
Po-661-07 a photoplethymography-based approach to atrial fibrillation-burden estimation in high-risk patients
Atrial fibrillation (AF) is the most common arrhythmia leading to hospital admission. Its incidence is linked to increased risk of stroke, congestive heart failure, and overall mortality. AF burden is a key determinant of outcomes, but accurate quantification can be limited by the cardiac monitoring period (typically days). Alternatively, longer-term monitoring comes at higher cost and often requires an invasive approach. The introduction of reliable wrist-worn devices may improve access to long-term monitoring of AF burden.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Charles A. Athill, Yuriko Tamura, Steven Szabados, Anthony Battisti, Jeffrey Ellis, Lori Crosson, Judith C. Lenane Source Type: research
Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation
This study aimed to assess procedural outcomes in patients with cirrhosis who underwent LAAO with a Watchman device by using a contemporary administrative claims database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Sahith Reddy Thotamgari, Aakash R. Sheth, Harsh P. Patel, John Bretzman, Robert C. Ward, Samarthkumar Thakkar, Jaimin T. Patel, Samuel J. Asirvatham, David R. Holmes, Alexander Egbe, Abhishek Deshmukh, Christopher V. DeSimone Tags: Research Letter Source Type: research
Effect of Recombinant Human Brain Natriuretic Peptide on Acute Carbon Monoxide Poisoning Complicated with Heart Failure with Reduced Ejection Fraction
Int Heart J. 2022;63(2):312-318. doi: 10.1536/ihj.21-170.ABSTRACTThis paper aims to observe the effect of recombinant human brain natriuretic peptide (rhBNP) on treatment of acute carbon monoxide poisoning (ACMP) complicated with heart failure with reduced ejection fraction (HFREF).A total of 103 patients with ACMP complicated with HFREF admitted to our department from October 2016 to March 2020 were observed. Patients were divided into control group (50 cases) and experimental group (53 cases). The control group was given diuretic, vasodilator, and digitalis treatment, and the experimental group was supplemented with rhBN...
Source: International Heart Journal - March 31, 2022 Category: Cardiology Authors: Wenpin Xu Weizhan Wang Qingmian Xiao Yan Wang Baoyue Zhu Pu Wang Source Type: research
